References

3. W. Sneader, Drug Discovery: The Evolution of Modern Medicines, Wiley, Chichester, UK, 1985.

5. K. J. Watling, The RBI Handbook, 4th ed, Sigma-RBI,Natick, MA, 2001.

6. G. R. Lenz, H. M. Nash, and S. Jinfal, Drug Discov. Today, 5,145-156 (2000).

7. G. Milligan, J. Cell. Sei., 114, 1265-1271 (2001).

8. K. A. Jones, B. Borowsky, J. A. Tamm, et al., Nature, 396,674-679 (1997).

9. J. H. White, A. Wise, M. J. Main, et al., Nature, 396,679-682 (1997).

10. M. Margeta-Mitrovic, Y. N. Jan, and L. Y. Jan., Proc. Natl. Acad. Sci. USA, 98, 14643-14648 (2001).

11. M. Rocheville, D. C. Lange, U. Kumar, et al., Science, 288, 154-157 (2000).

12. F. Liu, Q. Wan, Z. B. Pristupa, et al., Nature, 403,274-280 (2001).

13. B. A. Jordan, N. Trapadize, I. Gomes, et al., Proc. Natl. Acad. Sci. USA, 98, 343-348 (2001).

14. H. Mohler, J. M. Fritschy, and U. Rudolph, J. Pharmacol. Exp. Ther., 300, 2-8 (2002).

15. T. Yamakuraand K. Shimoji, Prog. Neurobiol.,

16. P. M. Sexton, A. Albiston, M. Morfis, and N. Tilakartne, Cell Signal., 13, 73-83 (2001).

17. J. C. Bermak and Q.-Y. Zhou, Mol. Znterven.,1, 282-287 (2001).

18. H. Husi, M. A. Ward, J. S. Choudhary, et al., Nature Neurosci., 3,661-669 (2000).

19. M. Kim, L.-H. Jiang, H. L. Wilson, et al., EMBO J., 20,6347-6358 (2001).

21. J. Monod, J. Wyman, and J.-P. Changeux, J Mol. Biol., 12, 88-118 (1965).

22. A. J. Clark, The Mode of Action of Drugs on Cells, Arnold, London, UK, 1933.

23. T. P. Kenakin, Nature Rev. Drug Discov., 1, 103-110 (2002).

24. D. E. Koshland, G. Nemethy, and D. Filmer, Biochemistry, 6, 365-387 (1966).

25. A. Christopoulos, Nature Rev. Drug Discov., 1, 198-210 (2002).

26. P. Cuatrecasas, Ann. Rev. Biochem., 43, 169214 (1974).

27. A. DeLean, J. M. Stadel, and R. J. Lefkowitz, J. Biol. Chem., 255, 7108-7117 (1980).

29. J. H. Gaddum, Pharmacol. Rev., 9, 211-218 (1957).

30. O. Arunlakshana and H. O. Schild, Br. J. Pharmacol.,14, 48-58 (1959).

31. E. J. Ariens, Arch. Int. Pharmacodyn., 99, 32-49 (1954).

32. J. Saunders and S. B. Freedman, Trends Pharmacol. Sci. Suppl. 70-75 (1989).

33. R. P. Stephenson, Br. J. Pharmacol., 11, 379392 (1956).

34. R. F. Furchgott, Ann Rev. Pharmacol., 4, 21-38 (1964).

35. T. P. Kenakin, Pharmacologic Analysis of Drug-Receptor Interaction, 3rd ed, Lippincott, Philadelphia, PA, 1997.

36. R. J. Tallarida, Drug Dev. Res., 19, 257-274 (1990).

37. D. E. Koshland, Proc. Natl. Acad. Sci. USA, 44, 98 (1958).

38. V. Hill, J. Physiol. (LondJ, 39,361-373 (1909).

39. W. Paton, Proc. Roy. Soc. Ser. B, 154, 21-69 (1961).

40. L. Limbird, Cell Surface Receptors, Nijhoff, Boston, MA, 1986.

41. B. Katz and S. Thesleff, J. Physiol. (.Und.), 138, 63-80 (1957).

42. H. O. Onaran, A. Scheer, S. Cotecchia, and T. Costa, Handbook Exp. Pharnacol., 148, 217280 (2000).

43. H. Frauenfelder, S. G. Sigar, and P. G. Wolynes. Science, 254, 1598-1603 (1991).

44. M. K. Dean, C. Higgs, R. E Smith, et al., J. Med. Chem., 44,4595-4614 (2001).

45. S. Larareno, P. Gharagozloo, D. Kuonen, et al., Mol. Pharmacol., 53, 573-589 (1998).

46. N. Le Novere and J. P. Changeux,J. Mol. Ecol., 40,155-172 (1995).

47. U. V. Lalo, Y. V. Pankratov, D. Arndts, and O. A. Krishtal, Brain Res. Bull., 54, 507-512 (2001).

48. A. Sharpe, J. Gehrmann, M. L. Loughnan, et al., Nature Neurosci., 4, 902-907 (2001).

49. T. P. Kenakin, Pharmacol. Rev., 48, 413-463 (1996).

50. P. Samama, G. Pei, T. Costa, et al., Mol. Pharmacol., 45, 390-394 (1994).

51. C. Braestrup and M. Nielsen, in R. W. Olsen and J. C. Venter, Eds., Benzodiazepine! GAB A Receptors and Chloride Channels: Structure and Functional Properties, Wiley-Liss, New York, 1986, pp. 167-184.

52. M. Lutz and T. P. Kenakin, Quantitative Molecular Pharmacology and Informatics In Drug Discovery, Wiley, Chichester, UK, 1999.

53. M. J. Smit, R. Leurs, A. E. Alewijnse, et al, Proc. Natl. Acad. Sci. USA, 93, 6802-6807

54. S. W. Edwards, C. M. Tan, and L. L. Limbird, Trends Pharmacol. Sci., 21, 304-308 (2000).

55. G. Vantini, Psychoneuroendocrinol., 17, 410410 (1992).

56. J. T. Coyle, D. L. Price, and M. L. Delong, Science, 219,1184-1190(1983).

57. T. P. Kenakin, R. A. Bond, and T. I. Bonner, Pharmacol. Rev., 44,351-362 (1992).

58. Available online at http//:biomedpda.com.

59. M. J. Gunthorpe, C. D. Benham, A. Randall, and J. B. Davis, Trends Pharmacol. Sci., 23, 183-191 (2002).

61. D. M. Mangelsdorf and R. M. Evans, Cell, 83, 841-850 (1995).

62. J. A. Brzostowski and A. R. Kimmel, Trends Biochem. Sci., 26, 291-297 (2001).

63. J. M. Herz and W. J. Thomsen, Encyclopedia Pharmaceutical Technology, Dekker, New York, 2002, pp. 2375-2395.

64. K. Palczewski, et al., Science, 289, 739-745 (2000).

65. K. Lundstrom, Curr. DrugDiscov.2002,29-33 (2002).

66. J. Bockaert and J. P. Pin, EMBO J., 18,17231729 (1999).

67. D. M. Berman and A. G. Gilman, J. Biol. Chem, 273,1269-1272 (1998).

68. M. Conti and S. L. C. Jin, Prog. Nucleic Acid Res. Mol. Biol, 63,1-38 (2000).

69. M. Bunemann and M. M. Hosey, J. Physiol., 517, 5-23 (1999).

70. R. J. Lefkowitz, J. Biol. Chem, 273, 1867718680 (1998).

71. E. Costa, Ann. Rev. Pharmacol. Toxicol., 38, 321-350 (1998).

72. U. Rudolph, F. Crestani, D. Benke, et al., Nature, 401, 796-800 (2001).

73. G. K. Lloyd and M. Williams, J. Pharmacol. Exp. Ther,, 292,461-467 (2000).

74. J.-P. Changeux and S. Edelstein, Neuron, 21, 959-980 (1998).

75. M. Le Noviere, T. Gr utter, and J.-P. Changeux, Proc. Natl. Acad. Sci. USA, 99, 3210-3215 (2002).

76. K. A. Jacobson, M. F. Jarvis, and M. Williams, J. Med. Chem, 45,4057-4093 (2002).

77. E. Enmark, M Pelto-Huikko, M. Grandien, et al,J. Clin. Endocrinol.Metab.,82,4258-4265

78. Y. Shang and M. Brown, Science, 295, 24652468 (2002).

80. M. Keyse, Curr. Opin. Cell Biol, 12, 186193 (2000).

81. S. Jaken and P. J. Parker, Bioessays, 22.3, 245-254 (2000).

82. D. S. Bredt and S. H. Snyder, Ann. Rev. Biochem., 63,175-195 (1994).

83. B. Wolf and D. R. Green, J. Biol. Chem, 274, 20049-20052 (1999).

84. S. Schoonbroodt and J. Piette, Biochem. Pharmacol., 60, 1075-1083 (2000).

85. P. Escher and W. Wahli, Mut. Res, 448, 121-138(2000).

86. S. K. Dower, Nature Immunol., 1, 367-368 (2000).

88. A. Wise, K. Gearing, and S. Rees, Drug Discov. Today, 7,235-246 (2002).

89. C. Mollereau, M. Parmentier, P. Mallieux, et al, FEBS Lett, 341, 33-38 (1994).

90. J. C. Meunier, C. Mollereau, L. Toll, et al, Nature, 377, 532-535 (1995).

91. W. Jenck, J. Wichmann, F. M. Dautzenberg, et al., Proc. Natl. Acad. Sci. USA, 97,4938-4943 (2000).

92. E. De Souza and D. E. Grigoriadis in K. L. Davis, D. Charney, J. T. Coyle, and C. Nemer-off,Eds., Psychopharmacology: Fifth Generation of Progress. Lippincott Williams and Wilkins, Philadelphia, PA, 2002, pp. 91-107.

93. B. Smit, N. I. Syed, D. Schaap, et al, Nature, 411,261-268 (2001).

94. K. Brejc, W. J. van Dijk, and R. V. Klaasen, et al. Nature, 411,269-276 (2001).

95. C. Felder and M. Glass, Ann. Rev. Pharmacol. Toxicol, 38,179-200 (1998).

96. S. M. Huang, T. Bisogno, T. Trevisani, et al., Proc. Natl. Acad. Sci. USA, 99, 8400-8405 (2002).

97. N. Dahwan, F. Sesselin, R. Raghubir, et al., Pharmacol. Rev, 48,567-592 (1996).

98. K. Mullis and F. A. Faloona, Methods Enzy-mol, 155, 335-350 (1987).

99. R. Oliphant and K. Struhl, Proc. Natl. Acad. Sci. USA, 86,9094-9098 (1989).

100. S. B. Liggett, N. J. Freedman, D. A. Schwinn, and R. J. Lefkowitz, Proc. Natl. Acad. Sci. USA, 90, 3665-3669 (1993).

101. L. Essioux, B. Destenaves, P. Jais, and F. Thomas in J. Licinio and M.-L. Wong, Eds.,

Pharmacogenomics, Wiley-VCH, Weinheim, Germany, 2002, pp. 57-82.

103. MJ.Marton, J. L.DiRisi, H. A Bennett, etal., Nature Med., 4,1293-1301 (1998).

104. A. D. Roses, Nature Rev. Drug Discov, 1, 541549 (2002).

105. J. F. Wang, B. Chen, and L. T. Young, Mol Brain Res, 70, 66-73 (1999).

106. P. Legrain, J. Wojcik, and J-M. Gauthier, Trends Genetics, 17,346-352 (2001).

107. A. R. Mendelsohn and R. Brent, Science, 284, 1948-1950 (1999).

108. P. Honore, K. Kage, J. Mikusa, et al. Pain, 99, 19-27 (2002).

109. S. L. Schreiber, Science, 287, 1964-1969 (2000).

110. G. M. Makara, J. Med. Chem, 44, 3563-3571 (2001).

111. C. J. Woolf and R. J. Mannion, Lancet, 353, 1959-1964 (1999).

112. R. G. Hill, Trends Pharmacol. Sci, 21, 244246 (2000).

113. L. M. Brzustowicz, K. A Hodginkson, W. C. Chow, et al, Science, 288, 678-682 (2000).

114. A. Sawa and S. H. Snyder, Science, 296, 692695 (2002).

115. D. F. Levinson, P. A. Holmans, C. Laurent, et al, Science, 296, 739-741 (2002).

116. M. L. Mimmack, M. Ryan, H. Baba, et al, Proc. Natl. Acad. Sci. USA, 99,4680-4685 (2002).

117. U. Bailer, F. Leisch, K. Meszaros, et al., Biol. Psychiatr, 52, 40-52 (2002).

118. M. Williams, J. T. Coyle, S. Shaikh, and M. W. Decker, Ann. Rep. Med. Chem., 36, 1-10 (2001).

119. A. P. Li, Drug Discov. Today 6, 357-366 (2001).

121. R. Bohachek, C. M. McMartin, and W. C. Guida, Med. Res. Rev, 16, 3-50 (1996).

122. M. A Navia and P. R. Chaturverdi, Drug Disco-Today, 1,179-189 (1996).

123. T. L. Blundell, H. Jhoti, and V. Abell, Nature Rev. Drug Discou, 1, 45-54 (2002).

124. B. Shuker, P. J. Hajduk, R. P. Meadows, and S. W. Fesik, Science, 274, 1531-1534 (1996).

125. W. P. Walters, M. T. Stahl, and M. A. Murko, Drug Discov. Today, 3, 160-178 (1998).

126. Ml. Kahn, Tetrahedron, 49,3433-3689 (1993).

127. M. Eguchi, R. Y. W. Shen, J. P. Shea, et al., J. Med. Chem, 45,1395-1398 (2002)

128. H. Jhoti, Trends Biotech, 19 (suppl), S67-S71 (2001).

129. J. Roth,Metabolism, 22,1059-1073 (1973).

130. D. Colquhoun, Mol. Znterven., 2, 128-131 (2002).

131. H. Snyder, J. Med. Chem, 26, 1667-1672 (1983).

132. M. McKinney in S. J. Enna and M. Williams, Eds., Current Protocol for Pharmacology, Wiley, New York, 1998, pp. 1.3.1-1.3.33.

133. Y.-C. Chengand W. C. Prusoff, Biochem. Pharmacol^, 3099-3108 (1972).

134. K. L. Whiteaker, J. P. Sullivan, and M. Go-palkrishnan In S. J. Enna, M. Williams, Eds, Current Protocol for Pharmacology, Wiley, New York, 2000, pp. 9.2.1-9.2.23.

135. S.J. Hill, J. G. Baker, and S. Rees, Curr. Opin. Pharmacol., 1, 526-532 (2001).

136. G. F. Graminski, C. K. Jayawickreme, M. N. Potenza, and M. R. Lerner, J. Biol. Chem., 268,5957-5964 (1993).

137. K. Truong and M. Ikura, Curr. Opin. Structural Biol, 11, 573-578 (2001).

138. A. J. Pope, U. M. Haupt, and K. J. Moore, Drug Discov. Today, 4,350-362 (1999).

139. H. M. Prosser, D. G. Cooper, I. T. Forbes, et al, Drug Dev. Res., 55, 197-209 (2002).

140. R. A. Coleman, W. P. Bowen, I. A. Baines, et al., Drug Discov. Today, 6,1116-1126 (2001).

141. A. Hodgson, Nature Biotech., 19, 722-726 (2001).

142. C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, Adv. Drug. Deliv. Rev, 23, 3-25 (1997).

143. D. F. Veber, S. R. Johnson, H. Y. Cheng, et al, J. Med. Chem, 45,2615-2623 (2002).

145. A. K. Mandagere, T. N. Thompson, and K.-K. Hwang J. Med. Chem, 45, 304-311 (2002).

146. L. R. Bandara and S. Kennedy, Drug Discov. Today, 7,411-418 (2002).

147. A. P. Beresford, H. E. Selick, and M. H. Tarbit, Drug Discov. Today,7,109-116 (2002).

148. P. Finn, Drug Discov. Today, 1, 363-370 (1996).

149. M. J. O'Neil, A Smith, P. E. Heckelman, etal. The Merck Index, 13th Edn, Merck, Rahway, NJ, 2001.

150. R. S. L. Chang, V. J. Lotti, R. L. Monaghan, et al. Science, 230, 177-179 (1985).

151. B. E. Evans, K. E. Rittle, M G. Bock, et al, J. Med. Chem., 31,2235-2246 (1988).

152. A. Harvey, Drug Discov. Today, 5, 294-300 (2000).

153. T. R. Brazelton and R. E. Morris, Curr. Opin. Immunol., 8, 710-720 (1996).

155. D. J. deVries and M. R. Hall, Drug Dev. Res, 33,61-173 (1994).

156. J. M. Riddle and J. X. Estes,Ant. Sei, 80,226234 (1992).

157. A. T. Bull, M. Goodfellow, and J. H. Slater, Ann. Rev. Microbiol, 46,219-252 (1992).

158. E. F. DeLong, Curr. Opin. Microbiol, 4, 290295 (2001).

159. G. S. Shen, R. T. Layer, and R. T. McCabe, DrugDiscou. Today, 5, 98-106 (2000).

160. B. M. Olivera, D. R. Hillyard, M. Marsh, and D. Yoshikami, Trends Biotechnol, 13, 422-426 (1995).

161. J. W. Daly H. M. Garraffo,and C. W. Myers, Pharm. News, 4, 9-14 (1997).

162. B. Badio, H. M. Garraffo, T. R. Spande, and J. W. Daly Med. Chem. Res, 4, 440-448 (1994).

163. A. W. Bannon, M. W. Decker, M. W. Holladay, et al, Science, 289, 77-80 (1998).

165. M. Ondetti, Ann. Rev. Pharmacol. Toxicol., 34, 1-16 (1994).

166. L. D. Byers and R. Wolfenden, Biochemistry, 12,2070-2078(1973).

167. D. J. Triggle in M. Epstein, Ed., Calcium Antagonists in Clinical Medicine, 2nd ed., Hanley & Belfus, Philadelphia, PA, 1997, pp. 1-26.

168. S. Goldmann and J. Stoltefuss,Angew. Chemie Int. Ed, 30,1559-1578 (1991).

169. D. Romer, H. H. Buscher, and R. C. Hill, et al, Nature, 298, 759-760 (1982).

170. C. Papaageorgiou and X. Borer, Bioorg. Med Chem. Lett, 6,267-272 (1996).

171. S. D. Donevan, S.T. Yamaguchi, and M. A. Ro-gawski,J. Pharmacol. Exp. Ther, 271, 25-29 (1994).

172. R. E. Johnson, E. R. Baizman, E. R. C. Becker, et al, J. Med. Chem, 36, 3361-3370 (1993).

173. D. M. Stout and A. I. Meyers, Chem. Rev., 82, 223-242 (1982).

174. D. J. Triggle, Cleveland Clin. J. Med, 59,617627 (1992).

175. T. Furukawa, T. Aukida, K. Suzuki, et al., Br. J. Pharmacol, 121, 1136-1140 (1997).

176. C. J. Cohen, S. Spires, and D. van Skiver, J. Gen. Physiol, 100, 703-728 (1992).

177. W. Hopf, R. Reddy, J. Hong and R. A Steinhardt, J. Biol. Chem, 271, 22358-22367

178. X. Zhang, J. W. Anderson, and D. Fedida, J. Phnrmacol. Exp. Ther. 281, 1247-1256

179. H. Miyawaki, F. Yamakazi, T. Furata, et al. Drug Dev. Res, 22,293-298 (1991).

180. K. Cooper, M J. Frayk, M H. Parry, et al, J. Med. Chem, 35,3115-3129 (1992).

181. A. M. van Rhee, J.-L. Wang, N. Melman, et al. J. Med. Chem, 39,2980-2989 (1996).

182. Trivedi, L. Potter-Lee, M. W. McConville, et al., Res. Commun. Mol. Path. Pharmacol., 88, 137-151 (1995).

183. M. Goplakrishnan, S. A. Buckner, K. L. Whi-taker et al., J. Pharmacol. Exp. Ther. (2002)in press.

184. J. L. Harper, C. S. Cameriini-Otero, A.-H. Li, et al., Biochem. Pharmacol., (2002) in press.

185. J. M. Wetzel, S. W. Miao, C. Forray, et al, J. Med. Chem, 38,1579-1581 (1995).

186. F. Horrobin, Nature Biotech, 19, 1099-1100 (2001).

187. J. Everett, M. Gardner, F. Pullen, et al. Drug Discov. Today, 6, 779-785 (2001).

188. A.W. Czarnik and J. A. Ellman, Ace. Chem. Res, 29,112-170 (1996).

189. J. R. Khosla and R. J. X. Zawada, Trends Biotechnol, 14,137-142 (1996).

190. J. R. Jacobsen, C. R. Hutchinson, D. E. Cane, and C. Khosla, Science, 277, 367-369 (1997).

191. C. A. Lesburg G. Zhai, D. E. Cone, and D. W. Christianson, Science, 277,1820-1824 (1997).

192. J. C. Sacchettini and C. D. Poulter, Science, 277,1788-1789 (1997).

194. A. A. Beaudry and G. F. Joyce, Science, 257, 635-641 (1992).

195. X.-Y. R Song T, J Torphy, D. E. Griswold, and D. Shealy, Mol. Interven., 2, 36-46 (2002).

196. B. Opalinska and A. M. Gerwitz, Nature Rev. Drug Discov, 1,503-514 (2002).

197. P. Estibeiro and J. Godfray, Trends Neurosci, 24, S56-S62 (2001).

198. M. Williams, T. Giordano, R. A Elder, H. J. Reiser, and G. L. Neil, Med. Res. Rev, 13,399448 (1993).

Was this article helpful?

0 0
Getting to Know Anxiety

Getting to Know Anxiety

Stop Letting Anxiety Rule Your Life And Take Back The Control You Desire Right Now! You don't have to keep letting your anxiety disorder run your life. You can take back your inner power and change your life for the better starting today! In order to have control of a thing, you first must understand it. And that is what this handy little guide will help you do. Understand this illness for what it is. And, what it isn't.

Get My Free Ebook


Post a comment